摘要
目的探讨胺碘酮、β受体阻滞剂及两者合用治疗急性心肌梗死(AMI)并发恶性室性心律失常的临床疗效。方法选择急性心肌梗死合并恶性室性心律失常136例,心功能按NYHA 分级为Ⅱ-Ⅲ级,随机分为胺碘酮治疗组、β受体阻滞剂治疗组和胺碘酮+小剂量β受体阻滞剂治疗组。结果各组治疗心率失常的近期疗效相比有统计学意义(x2=14．1341,P<0．01),胺碘酮组与胺碘酮+小剂量β受体阻滞剂组均优于β受体阻滞剂组(x2=4．9851,P<0．05),胺碘酮+小剂量β受体阻滞荆组优于胺碘嗣组(x2=13．0213,P<0．01);随访两年后心血管事件发生率三组相比有统计学意义(x2=17．1669,P<0．01),胺碘酮+小剂量β受体阻滞剂组优于另外两组。结论AMI早期联合应用胺碘酮+小剂量β受体阻滞荆可预防心血管事件及恶性室性心律失常的发生。
Objective To explore the therapeutic effects of amiodarone, β-receptor inhibitor and associated two medicines on AMI complicated malignant ventricular arrhythmia. Methods 136 cases of AMI complicated malignant ventricular arrhythmia were selected, cardiac function were classified Ⅱ～Ⅲgrade by NYHA. And those cases were divided into three groups： amiodarone group, β-receptor inhibitor group and associated two medicines group. Results The therapeutic effects in short-term and long-term in three groups had a statistics significance（X^2 = 14. 1341, P〈0. 01）; follow-up two years the incidence rate of cardiovascular events and malignant ventricular arrhythrnia of the three groups had a statistics significance（X^2 = 17. 1669, P〈0. 01）. Conclusion Associate using amiodarone and small doseβ-receptor inhibitor in the early phase of AMI could prevent cardiovascular events and malignant ventricular arrhythmia.
出处
《贵州医药》
CAS
2006年第3期211-213,共3页
Guizhou Medical Journal
关键词
胺碘酮
Β受体阻滞剂
室性心律失常
Amiodarone β-receptor inhibitor Ventricular arrhythmia
